BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study
- PMID: 33452586
- PMCID: PMC7940263
- DOI: 10.1007/s00125-020-05362-7
BMI and BMI change following incident type 2 diabetes and risk of microvascular and macrovascular complications: the EPIC-Potsdam study
Abstract
Aims/hypothesis: Studies suggest decreased mortality risk among people who are overweight or obese compared with individuals with normal weight in type 2 diabetes (obesity paradox). However, the relationship between body weight or weight change and microvascular vs macrovascular complications of type 2 diabetes remains unresolved. We investigated the association between BMI and BMI change with long-term risk of microvascular and macrovascular complications in type 2 diabetes in a prospective cohort study.
Methods: We studied participants with incident type 2 diabetes from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort, who were free of cancer, cardiovascular disease and microvascular disease at diagnosis (n = 1083). Pre-diagnosis BMI and relative annual change between pre- and post-diagnosis BMI were evaluated in multivariable-adjusted Cox models.
Results: There were 85 macrovascular (myocardial infarction and stroke) and 347 microvascular events (kidney disease, neuropathy and retinopathy) over a median follow-up of 10.8 years. Median pre-diagnosis BMI was 29.9 kg/m2 (IQR 27.4-33.2), and the median relative annual BMI change was -0.4% (IQR -2.1 to 0.9). Higher pre-diagnosis BMI was positively associated with total microvascular complications (multivariable-adjusted HR per 5 kg/m2 [95% CI]: 1.21 [1.07, 1.36], kidney disease 1.39 [1.21, 1.60] and neuropathy 1.12 [0.96, 1.31]) but not with macrovascular complications (HR 1.05 [95% CI 0.81, 1.36]). Analyses according to BMI categories corroborated these findings. Effect modification was not evident by sex, smoking status or age groups. In analyses according to BMI change categories, BMI loss of more than 1% indicated a decreased risk of total microvascular complications (HR 0.62 [95% CI 0.47, 0.80]), kidney disease (HR 0.57 [95% CI 0.40, 0.81]) and neuropathy (HR 0.73 [95% CI 0.52, 1.03]), compared with participants with a stable BMI; no clear association was observed for macrovascular complications (HR 1.04 [95% CI 0.62, 1.74]). The associations between BMI gain compared with stable BMI and diabetes-related vascular complications were less apparent. Associations were consistent across strata of sex, age, pre-diagnosis BMI or medication but appeared to be stronger among never-smokers compared with current or former smokers.
Conclusions/interpretation: Among people with incident type 2 diabetes, pre-diagnosis BMI was positively associated with microvascular complications, while a reduced risk was observed with weight loss when compared with stable weight. The relationships with macrovascular disease were less clear.
Keywords: BMI; CVD; Diabetes-related vascular complications; Nephropathy; Neuropathy; T2D; Weight change.
Figures
Similar articles
-
Fetuin-A and risk of diabetes-related vascular complications: a prospective study.Cardiovasc Diabetol. 2022 Jan 8;21(1):6. doi: 10.1186/s12933-021-01439-8. Cardiovasc Diabetol. 2022. PMID: 34998417 Free PMC article.
-
Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study.J Diabetes Complications. 2019 Aug;33(8):572-578. doi: 10.1016/j.jdiacomp.2019.04.016. Epub 2019 May 10. J Diabetes Complications. 2019. PMID: 31167710
-
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program).Cardiovasc Diabetol. 2018 Nov 28;17(1):150. doi: 10.1186/s12933-018-0787-8. Cardiovasc Diabetol. 2018. PMID: 30486889 Free PMC article.
-
Macrovascular effects and safety issues of therapies for type 2 diabetes.Am J Cardiol. 2011 Aug 2;108(3 Suppl):25B-32B. doi: 10.1016/j.amjcard.2011.03.014. Am J Cardiol. 2011. PMID: 21802578 Review.
-
The vascular complications of diabetes: a review of their management, pathogenesis, and prevention.Expert Rev Endocrinol Metab. 2024 Jan-May;19(1):11-20. doi: 10.1080/17446651.2023.2279533. Epub 2024 Jan 1. Expert Rev Endocrinol Metab. 2024. PMID: 37947481 Review.
Cited by
-
Treat Obesity to Treat Type 2 Diabetes Mellitus.Diabetes Ther. 2024 Feb 4. doi: 10.1007/s13300-024-01536-3. Online ahead of print. Diabetes Ther. 2024. PMID: 38310627 Review.
-
Effects of sleep duration and changes in body mass index on diabetic kidney disease: a prospective cohort study.Front Endocrinol (Lausanne). 2023 Oct 26;14:1278665. doi: 10.3389/fendo.2023.1278665. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37964958 Free PMC article.
-
Age at diagnosis, diabetes duration and the risk of cardiovascular disease in patients with diabetes mellitus: a cross-sectional study.Front Endocrinol (Lausanne). 2023 May 8;14:1131395. doi: 10.3389/fendo.2023.1131395. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37223032 Free PMC article.
-
The Risk of Type 2 Diabetes Mellitus according to Changes in Obesity Status in Late Middle-Aged Adults: A Nationwide Cohort Study of Korea.Diabetes Metab J. 2023 Jul;47(4):514-522. doi: 10.4093/dmj.2022.0159. Epub 2023 Apr 25. Diabetes Metab J. 2023. PMID: 37096375 Free PMC article.
-
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?Drugs. 2023 Apr;83(6):469-477. doi: 10.1007/s40265-023-01852-1. Epub 2023 Mar 21. Drugs. 2023. PMID: 36941489
References
-
- Zaccardi F, Dhalwani NN, Papamargaritis D, et al. Nonlinear association of BMI with all-cause and cardiovascular mortality in type 2 diabetes mellitus: a systematic review and meta-analysis of 414,587 participants in prospective studies. Diabetologia. 2017;60(2):240–248. doi: 10.1007/s00125-016-4162-6. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
